Know Cancer

or
forgot password

Single Nucleotide Polymorphism (SNP)-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants


N/A
18 Years
N/A
Open (Enrolling)
Both
Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Multiple Myeloma

Thank you

Trial Information

Single Nucleotide Polymorphism (SNP)-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants


Subjects will be provided with a saliva collection kit which can be used at home. Subjects
will return the collection kit in a paid, pre-addressed mailer to the laboratory at
Biomodels. The laboratory will isolate and store the DNA located in the cells of the saliva.
A portion of this DNA will be used to analyze the different forms of genes. The remainder of
the DNA will be destroyed when this study is completed. Biomodels will not be provided with
patient identifiers.

The investigators will also collect information from medical records, including information
about diagnosis, treatment, stem cell transplantation and post-transplantation outcomes.
This information will be de-identified.


Inclusion Criteria:



- Have given informed consent to submit a sample of saliva for DNA isolation and SNP
analysis

- Have undergone autologous HSCT for treatment of Hodgkin's or non-Hodgkin's lymphoma
or multiple myeloma at the Dana-Farber Cancer Institute from 1/1/2006 through
6/30/2010

- Have medical records identifying whether the participants did or did not develop
severe mucositis

Exclusion Criteria:

- Received Palifermin (Kepivance) prior to their conditioning regimen

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Retrospective

Outcome Measure:

Develop and validate a clinically applicable SNP-based screening platform for mucositis risk

Outcome Description:

Develop and validate a clinically applicable SNP-based screening platform that will define mucositis risk among patients undergoing conditioning regimens for HSCT

Outcome Time Frame:

2 years

Safety Issue:

No

Principal Investigator

Joseph Antin, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Dana-Farber Cancer Institute

Authority:

United States: Institutional Review Board

Study ID:

10-236

NCT ID:

NCT01402687

Start Date:

October 2010

Completion Date:

October 2013

Related Keywords:

  • Hodgkin's Lymphoma
  • Non-Hodgkin's Lymphoma
  • Multiple Myeloma
  • Stem Cell Transplant
  • Mucositis
  • Hodgkin Disease
  • Lymphoma
  • Lymphoma, Non-Hodgkin
  • Multiple Myeloma
  • Neoplasms, Plasma Cell
  • Stomatitis
  • Mucositis

Name

Location
Dana-Farber Cancer Institute Boston, Massachusetts  02115